全球裁员365人！又一Biotech放弃细胞疗法

Core Insights - Galapagos announced the gradual shutdown of its cell therapy business due to unsuccessful attempts to sell the division, impacting 365 jobs across Europe, China, and the U.S. [1] - The company received multiple non-binding offers since May but deemed them unfeasible after evaluation [1] - The strategic decision to terminate the cell therapy business aims to reallocate funds towards developing new therapeutic pipelines [1] Market Reaction - Following the announcement, Galapagos' stock price dropped by 14% in early trading [3]